{"id":1139,"text":"Patients commonly take complementary medicines in conjunction with conventional drugs without clear evidence of safety or the risk of herb–drug interactions.","label":[],"Comments":[]}
{"id":1140,"text":"The aim of this study was to assess potential pharmacokinetic (PK) and pharmacodynamic (PD) interactions between St John's wort and gliclazide in healthy subjects with different cytochrome P450 2C9 (CYP2C9) genotypes.","label":[[113,127,"Herb name"],[132,142,"Drug"],[146,153,"Pathology"],[178,216,"Parameter"]],"Comments":[]}
{"id":1141,"text":"A crossover controlled study was conducted in 21 healthy subjects.","label":[[2,28,"Study"],[46,65,"Cohort"],[49,56,"Pathology"]],"Comments":[]}
{"id":1142,"text":"Each received gliclazide (80 mg) either alone or during 15 days treatment with St John's wort.","label":[[14,24,"Drug"],[26,31,"Amount"],[49,63,"Duration"],[79,93,"Herb name"]],"Comments":[]}
{"id":1143,"text":"The area under the plasma concentration–time curve (AUC St John's wort significantly altered gliclazide pharmacokinetics in all except for four healthy subjects.","label":[[0,55,"Parameter"],[56,71,"Herb name"],[93,103,"Drug"],[93,120,"Parameter"],[139,143,"Amount"],[144,151,"Pathology"]],"Comments":[]}
{"id":1144,"text":"The mean ratio and 90% confidence interval (CI) of gliclazide AUC Treatment with St John's wort significantly increases the apparent clearance of gliclazide which is independent of CYP2C9 genotype.","label":[[51,61,"Drug"],[62,65,"Parameter"],[81,95,"Herb name"],[120,142,"Parameter"],[146,156,"Drug"],[181,196,"Parameter"]],"Comments":[]}
{"id":1145,"text":"People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.","label":[[12,20,"Pathology"]],"Comments":[]}
{"id":1146,"text":"Chemical structure of gliclazide.","label":[[22,32,"Drug"]],"Comments":[]}
{"id":1147,"text":"Mean plasma gliclazide concentration–time profile in control and St John's wort treatment phases.","label":[[0,36,"Parameter"],[12,22,"Drug"],[65,79,"Herb name"]],"Comments":[]}
{"id":1148,"text":"Error bars represent s.d.","label":[],"Comments":[]}
{"id":1149,"text":"(n=21).","label":[],"Comments":[]}
{"id":1150,"text":"Individual gliclazide (a) maximum plasma concentration (C Mean changes in (a) glucose concentrations and (b) insulin concentration in 21 healthy subjects after single oral dose of 80 mg gliclazide alone and during co-administration with St John's wort (300 mg three times daily for 15 days) (error bars represent s.d.).","label":[[11,21,"Drug"],[26,54,"Parameter"],[78,99,"Parameter"],[109,130,"Parameter"],[134,153,"Cohort"],[137,144,"Pathology"],[160,176,"Frequency"],[180,185,"Amount"],[186,196,"Drug"],[237,251,"Herb name"],[253,259,"Amount"],[260,277,"Frequency"],[278,289,"Duration"]],"Comments":[]}
{"id":1151,"text":"Gliclazide apparent clearance (CL\/F) of three groups of CYP2C9 genotypes in gliclazide only phase.","label":[[0,10,"Drug"],[11,36,"Parameter"],[56,72,"Parameter"],[76,86,"Drug"]],"Comments":[]}
{"id":1152,"text":"(‘—' indicates mean in each group, the solid circle represents a subject with CYP2C9*2\/*2 genotype).","label":[[78,98,"Parameter"]],"Comments":[]}
{"id":1153,"text":"Pharmacokinetic parameters of gliclazide in 21 healthy subjects after a single oral dose of 80 mg gliclazide or co-administered with St John's wort (300 mg three times daily) Abbreviations: AUC Ratio is presented as mean and 90% CI, and all others are presented as mean and 95% CI.","label":[[30,40,"Drug"],[44,63,"Cohort"],[47,54,"Pathology"],[72,88,"Frequency"],[92,97,"Amount"],[98,108,"Drug"],[133,147,"Herb name"],[149,155,"Amount"],[156,173,"Frequency"],[190,193,"Parameter"]],"Comments":[]}
{"id":1154,"text":"Pharmacodynamic effects of gliclazide in 21 healthy subjects after a single oral dose of 80 mg gliclazide or co-administered with St John's wort (300 mg three times daily) Abbreviations: AUC Data are presented as mean±s.d., except for t Genotype frequency and gliclazide CL\/F in 21 subjects in gliclazide only phase Abbreviation: CL\/F, apparent clearance.","label":[[27,37,"Drug"],[41,60,"Cohort"],[44,51,"Pathology"],[69,85,"Frequency"],[89,94,"Amount"],[95,105,"Drug"],[130,144,"Herb name"],[146,152,"Amount"],[153,170,"Frequency"],[187,190,"Parameter"],[235,255,"Parameter"],[260,270,"Drug"],[271,275,"Parameter"],[279,290,"Cohort"],[294,304,"Drug"],[330,334,"Parameter"],[336,354,"Parameter"]],"Comments":[]}
{"id":1155,"text":"Data shown was not to represent population frequency; data are presented as median and range.","label":[],"Comments":[]}
